A Phase III trial evaluating adjuvant treatment with intismeran autogene in combination with KEYTRUDA (pembrolizumab) showed positive results in treating patients with completely resected stage IIB-IV melanoma.
The U.S. Food and Drug Administration has approved Takeda’s Orzeyful (oveporexton) tablets to treat narcolepsy type 1 in adults.
A new study has found infants are far more vulnerable than older children to severe illness from viruses such as influenza, respiratory syncytial virus (RSV), human metapneumovirus (hMPV) and SARS-CoV-2.
The U.S. Food and Drug Administration has approved mFLUSIVA (mRNA-1010), a new vaccine against seasonal influenza, for use in all adults 50 years and older.
Researchers have developed an experimental therapeutic nasal DNA vaccine for tuberculosis.
Scientists have developed a new HIV vaccine that has the potential to protect humans from developing HIV infection and AIDS.
The Bacillus Calmette-Guérin accine may alter immune activity around the brain and change levels of a protein closely associated with Alzheimer’s disease in older adults without evidence of the condition.
FDA has approved Tregzi, the first regulatory T (Treg) cell-based immunotherapy for improving chronic graft-versus-host disease (GVHD)-free survival in adult patients with blood cancers undergoing allogeneic hematopoietic stem cell transplantation.
The Healthcare Advisory Committee will develop actionable policy solutions, advance accountability for safety and more.
The new federal advisory body, the Healthcare Advisory Committee, will provide advice on modernizing healthcare in the U.S.
FDA-approved Kresladi (marnetegragene autotemcel) is the first gene therapy treating leukocyte adhesion deficiency type I (LADI).
A UTHealth study found adults 65 and older had a lower risk of developing Alzheimer’s disease after receiving a high-dose flu vaccine.